PSMA PET Imaging in Biochemical Recurrence: Clinical Approaches and Data-Driven Decisions
Panelists discuss how PSMA PET imaging plays a crucial role in detecting biochemical recurrence of prostate cancer, offering superior sensitivity and specificity compared with conventional imaging methods. In clinical practice, PSMA PET is typically ordered when there is a rise in prostate-specific antigen (PSA) levels post treatment, indicating potential recurrence. The imaging results significantly influence treatment decisions such as distinguishing between localized salvage therapy and systemic treatments. Pivotal trials have demonstrated the efficacy of various tracers.
Video content above is prompted by the following:
- Briefly discuss the role of PSMA PET imaging in assessing for biochemical recurrence and how imaging guides treatment decisions in this setting.
- What is your typical approach when monitoring for biochemical recurrence in this setting?
- When do you typically order PSMA PET imaging when monitoring for disease recurrence?
- How does PSMA PET imaging guide your treatment decisions in this setting?
- What do available data from pivotal trials demonstrate, and how do these findings inform your decisions in this setting?
- LOCATE – Axumin (fluciclovine F18). Andriole et al. J Urol. 2019
- PSMA-BCR – Illuccix (gallium Ga68 gozetotide). Calais et al. J Nucl Med. 2018
- CONDOR – Pylarify (piflufolastat F18). Morris et al. Clin Cancer Res. 2021
- SPOTLIGHT – Posluma (flotufolastat F18). Jani et al. J Urol. 2023
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
